Marketing & Communications
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
Merck Consumer Health CMO Atilla Cansun also talks about about why the company is focused on preparing society for an average lifespan of 100 years.
Judges were impressed by Abbott's use of Tumblr to increase awareness of Lasik procedures among millennials.
The inside story on a campaign for the ages, as told by the individuals who worked on it.
One critical aspect of oncology drugmakers' business remains firmly rooted in the past. That's customer experience.
The Facebook for doctors launches Pages, allowing healthcare companies to establish a presence on Sermo and engage with physicians.
Here's my biggest gripe: Innovation teams should be driving innovation for their particular business, not just for marketing and communications.
Patients and doctors are looking for orchestrated customer engagement and expect omnichannel excellence. Are healthcare marketers ready?
Omnichannel as company commitment is nothing new to technical marketing in pharma. Marketers now need a broader omnichannel funnel continuously open to deeper customer engagement.
Here are points of view from five sector pros on harmonizing healthcare campaigns in today's complex marketing world.
By breaking down traditional organizational silos to bring together the chief medical officer and the chief marketing officer, companies can unite the forces of clinical best practices with direct-to-consumer response marketing.
Pharma's efforts to evolve restrictions about off-label marketing move forward.
Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill
The Medical Information Working Group and the Washington Legal Foundation filed briefs in support of Amarin.
Amgen's PCSK9 inhibitor is the second in its class to get an FDA panel endorsement; a new drug could threaten Shire's hold on a rare-disease category; a study shows pharma invests less in Hispanic audiences than in other groups
The legislation would allow drugmakers to share economic information with payers beyond what is included on the FDA-approved label.
The company said revenue from pharmaceutical and medical device sponsorships and advertisements rose 10.7% but the company put some initiatives on hold.
The patient journey concept needs a reboot, according to executives at the inaugural MM&M Transforming Healthcare conference.
A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.
With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.
Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.
The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.
FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.
A look at the content that grabbed most reader interest over the past year.
BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.
The driver on NASCAR and other racing circuits will help challenge consumers to improve their health habits.
A trio of doctors make a case for putting limits on digital promotions, including those in EHRs and through social networks.
The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.
Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.
Regulatory Focus reports that the regulator has issued a Warning Letter to AB Science for marketing its canine tumor drug Kinavet for unapproved, off-label uses.